Literature DB >> 23597770

Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus.

Ajay D Rao1, Ravi V Shah, Rajesh Garg, Siddique A Abbasi, Tomas G Neilan, Todd S Perlstein, Marcelo F Di Carli, Michael Jerosch-Herold, Raymond Y Kwong, Gail K Adler.   

Abstract

Myocardial extracellular matrix expansion and reduced coronary flow reserve (CFR) occur in patients with type 2 diabetes mellitus without heart failure or coronary artery disease. Because aldosterone is implicated in the pathophysiology of cardiac fibrosis and vascular injury, the aim of this study was to test the hypothesis that aldosterone is associated with extracellular matrix expansion and reduced CFR in type 2 diabetes mellitus. Patients with type 2 diabetes mellitus without evidence of coronary artery disease were recruited. Blood pressure, lipid management, and glycemic control were optimized over 3 months. Cardiac magnetic resonance imaging with T1 mapping was used to measure myocardial extracellular volume (ECV). Cardiac positron emission tomography was used to assess CFR. On a liberal, 250 mEq/day sodium diet, 24-hour urinary aldosterone and change in serum aldosterone with angiotensin II stimulation were measured. Fifty-three participants with type 2 diabetes (68% men, mean age 53 ± 7 years, mean body mass index 32.2 ± 4.3 kg/m², mean glycosylated hemoglobin 6.8 ± 0.7%, mean systolic blood pressure 126 ± 14 mm Hg) without infarction or ischemia by cardiac magnetic resonance and positron emission tomography were studied. Subjects had impaired CFR (2.51 ± 0.83) and elevated ECV (0.36 ± 0.05), despite normal echocardiographic diastolic function and normal left ventricular function. Myocardial ECV, but not CFR, was positively associated with 24-hour urinary aldosterone excretion (r = 0.37, p = 0.01) and angiotensin II-stimulated aldosterone increase (r = 0.35, p = 0.02). In a best-overall multivariate model (including age, gender, body mass index, glycosylated hemoglobin, and blood pressure), 24-hour urinary aldosterone was the strongest predictor of myocardial ECV (p = 0.004). In conclusion, in patients with type 2 diabetes mellitus without coronary artery disease, aldosterone is associated with myocardial extracellular matrix expansion. These results implicate aldosterone in early myocardial remodeling in type 2 diabetes mellitus.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23597770      PMCID: PMC3957437          DOI: 10.1016/j.amjcard.2013.02.060

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.

Authors:  George Suzuki; Hideaki Morita; Takayuki Mishima; Victor G Sharov; Anastassia Todor; Elaine J Tanhehco; Amy E Rudolph; Ellen G McMahon; Sidney Goldstein; Hani N Sabbah
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology.

Authors:  Martin Ugander; Abiola J Oki; Li-Yueh Hsu; Peter Kellman; Andreas Greiser; Anthony H Aletras; Christopher T Sibley; Marcus Y Chen; W Patricia Bandettini; Andrew E Arai
Journal:  Eur Heart J       Date:  2012-01-24       Impact factor: 29.983

3.  Evidence for cardiomyopathy in familial diabetes mellitus.

Authors:  T J Regan; M M Lyons; S S Ahmed; G E Levinson; H A Oldewurtel; M R Ahmad; B Haider
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.

Authors:  Jin H Li; Xiao R Huang; Hong-Jian Zhu; Matthew Oldfield; Mark Cooper; Luan D Truong; Richard J Johnson; Hui Y Lan
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

5.  Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes.

Authors:  Marcelo F Di Carli; James Janisse; George Grunberger; Joel Ager
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

6.  Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

Authors:  R Rocha; C T Stier; I Kifor; M R Ochoa-Maya; H G Rennke; G H Williams; G K Adler
Journal:  Endocrinology       Date:  2000-10       Impact factor: 4.736

7.  Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Authors:  Bertram Pitt; Nathaniel Reichek; Roland Willenbrock; Faiez Zannad; Robert A Phillips; Barbara Roniker; Jay Kleiman; Scott Krause; Daniel Burns; Gordon H Williams
Journal:  Circulation       Date:  2003-09-29       Impact factor: 29.690

8.  Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus.

Authors:  John K Boyer; Srihari Thanigaraj; Kenneth B Schechtman; Julio E Pérez
Journal:  Am J Cardiol       Date:  2004-04-01       Impact factor: 2.778

9.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

Authors:  C G Brilla; K T Weber
Journal:  J Lab Clin Med       Date:  1992-12

10.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

View more
  13 in total

Review 1.  Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 2.  Cardiac MRI: a central prognostic tool in myocardial fibrosis.

Authors:  Bharath Ambale-Venkatesh; João A C Lima
Journal:  Nat Rev Cardiol       Date:  2014-10-28       Impact factor: 32.419

Review 3.  Role of cardiac MRI in diabetes.

Authors:  Ravi V Shah; Siddique A Abbasi; Raymond Y Kwong
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

Review 4.  Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients.

Authors:  Greicy Mara Mengue Feniman De Stefano; Silméia Garcia Zanati-Basan; Laercio Martins De Stefano; Viviana Rugolo Oliveira E Silva; Patrícia Santi Xavier; Pasqual Barretti; Roberto Jorge da Silva Franco; Jacqueline Costa Teixeira Caramori; Luis Cuadrado Martin
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-04-27

Review 5.  Myocardial T1 mapping: modalities and clinical applications.

Authors:  Christine L Jellis; Deborah H Kwon
Journal:  Cardiovasc Diagn Ther       Date:  2014-04

6.  Hepatocyte growth factor regulates the TGF-β1-induced proliferation, differentiation and secretory function of cardiac fibroblasts.

Authors:  Xin Yi; Xiaoyan Li; Yanli Zhou; Shan Ren; Weiguo Wan; Gaoke Feng; Xuejun Jiang
Journal:  Int J Mol Med       Date:  2014-05-16       Impact factor: 4.101

7.  The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study.

Authors:  Abdulghani M Larghat; Peter P Swoboda; John D Biglands; Mark T Kearney; John P Greenwood; Sven Plein
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-08-12       Impact factor: 6.875

8.  Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.

Authors:  Rajesh Garg; Ajay D Rao; Maria Baimas-George; Shelley Hurwitz; Courtney Foster; Ravi V Shah; Michael Jerosch-Herold; Raymond Y Kwong; Marcelo F Di Carli; Gail K Adler
Journal:  Diabetes       Date:  2014-08-14       Impact factor: 9.461

9.  Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain.

Authors:  Yukun Cao; Wenjuan Zeng; Yue Cui; Xiangchuang Kong; Miao Wang; Jie Yu; Shan Zhang; Jing Song; Xu Yan; Andreas Greiser; Heshui Shi
Journal:  Cardiovasc Diabetol       Date:  2018-01-04       Impact factor: 9.951

Review 10.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.